Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03609593
Title Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nicole Lamanna
Indications

chronic lymphocytic leukemia

Therapies

Rituximab

Bendamustine + Rituximab

Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.